Timeline
CEPI
Oslo-based coalition funding pandemic vaccine development and manufacturing readiness across outbreak-prone diseases.
18 of 18 entries (17 events, 1 interactions)
Filters
#14 27 Aug
Awarded up to US$16.5m for a Bundibugyo vaccine trial
Pandemics and Biosecurity: CEPI awards Minapharm US$16.5m for Ebola#14 27 Aug
#13 19 Aug
Awarded US$4.17 million to four cross-reactivity studies
Pandemics and Biosecurity: $4.17m to test Zaire vaccine antibodies#13 19 Aug
Mentioned in: 70,000 Ervebo doses, 20,000 as a trial
Pandemics and Biosecurity#13 2 Aug
Committed up to US$50 million to the programme
Pandemics and Biosecurity: Moderna doses first human in Truro#12 31 Jul
Announced up to $8.5m for the Bundibugyo-specific candidate
Pandemics and Biosecurity: CEPI puts a Bundibugyo vaccine in trials#9 2 Jul
Mentioned in: Ebola trial doses its first patient
Pandemics and Biosecurity#8 25 Jun
Mentioned in: Kerala Nipah quiet two weeks on
Pandemics and Biosecurity#7 8 Jun
Awarded Public Health Vaccines LLC $1.9m on 9 June for fourth Bundibugyo rVSV vaccine candidate seed stock
Pandemics and Biosecurity: CEPI funds a fourth Ebola vaccine#6 1 Jun
Committed $62m on 1 June across three Bundibugyo vaccine platforms
Pandemics and Biosecurity: CEPI and GAVI commit $112m, no treatment yet#5 1 Jun
Mentioned in: Only Ebola treatment still cannot dose
Pandemics and Biosecurity#5 26 May
Mentioned in: Donors pledge $500m, 57% over target
Pandemics and Biosecurity#4 21 May
Committed $54.3m to fund the Moderna mRNA-1018 H5N1 Phase 3 trial after HHS pulled US funding
Pandemics and Biosecurity: CEPI rescues Moderna H5N1 vaccine trial#3 17 May
Mentioned in: No approved Ebola drug works on Bundibugyo
Pandemics and Biosecurity#2 12 May
Mentioned in: Idaho dairy H5N1: 1 to 59 herds in twelve days
Pandemics and Biosecurity#2 12 May
Mentioned in: B3.13 replicates better in human nasal tissue
Pandemics and Biosecurity#1 22 Apr
Announced first Phase 3 trial of mRNA H5N1 vaccine candidate and expanded partnerships with Pasteur Network and PAHO
Pandemics and Biosecurity: Moderna begins Phase 3 H5N1 mRNA trial#1 31 Mar